Lumicell aims $29m Series C at pivotal breast cancer trial and expansion into other cancers

This article was originally published here
Share

LumicellWith $28.7 million from a recently-closed Series C round, Lumicell reported today that it plans to launch a pivotal trial of its image-guided cancer surgery tech in breast cancer.

The Wellesley, Mass.-based company added that it hopes to expand its clinical program into other solid tumor cancers, including lung, ovarian and brain cancer.

Get the full story at our sister site, Drug Delivery Business News.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply